Cellumen to Focus on Discovery Toxicology After Spin Out of Personalized Med Unit | GenomeWeb
Cellumen announced this week that it will spin out its personalized medicine unit into a separate entity to be called Cernostics Pathology. The new company will provide digital imaging pathology and tissue-based diagnostic products and services.
A Cellumen official told Cell-Based Assay News that Cernostics will build on Cellumen’s current collaborations, including its partnership with the Mayo Clinic and Foundation, to develop an advanced breast cancer diagnostic and theranostic test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.